Samsung Medison, a leading company in South Korea's medical device industry, is celebrating its 40th anniversary this year by investing heavily to become a top player in the diagnostic ultrasound equipment sector.

Over the past 40 years, Samsung Medison has grown into a global medical device company, supplying diagnostic ultrasound equipment to over 100 countries worldwide and achieving more than 90% of its revenue through exports.

Since Samsung Group acquired this company in 2011, Samsung Medison has consistently strengthened its product competitiveness through technology development, including improvements in imaging performance, the development of AI-powered diagnostic assistance features, and the implementation of user-centric designs.

As a result, Samsung Medison showed over 14% growth in the first half of this year compared to the same period last year, and it is anticipated to record its all-time highest annual sales.

Strong growth in the first half was driven by winning public tenders in multiple regions, including Europe, and expanding its presence in large hospitals across the U.S.

Samsung Medison plans to take a leadership position in the diagnostic ultrasound equipment industry through comprehensive investments in future growth, including ▲Strengthening global sales capabilities ▲Securing next-generation technologies like AI ▲Expanding its portfolio and production capacity.

To sustain its high growth in the second half of the year, Samsung Medison plans to recruit top talent, primarily in the U.S. and Europe, to enhance its direct sales capabilities. It will also subdivide and establish specialized sales organizations by medical division across different regions to boost its responsiveness to local markets.

Additionally, the company aims to accelerate revenue growth by exploring new large markets, including Australia, Canada, and Mexico.


The company also plans to focus on securing next-generation technologies, such as AI, which have recently become a hot topic, to ensure growth through maintaining a 'competitive edge in technology.'

Currently, Samsung Medison is establishing an R&D system focused on AI capabilities and actively pursuing strategic partnerships with leading global medical institutions.

It plans to expand the utilization of infrastructure, such as Samsung Electronics' overseas research institutes, and establish Innovation Labs and Next Generation Tech Labs locally. These efforts will drive the development of next-generation ultrasound technologies and diagnostic solutions while accelerating new market penetration.

Furthermore, Samsung Medison will actively expand its portfolio beyond obstetrics and gynecology and radiology to include divisions such as cardiology·point-of-care diagnostics.

The company aims to increase its global market share by strengthening its product lineup with AI features that automatically visualize·quantify the size of major organs and disease indicators in real time across various divisions, such as the heart, liver, and uterus.

In line with increasing global demand, the company is also actively pursuing the expansion of its production facilities.

The Hongcheon plant, currently undergoing expansion, will incorporate automation systems and smart processes, with plans to increase annual production capacity by over 50% by 2026.

By 2030, when the expansion of the second plant is complete, the company aims to more than double its current production while also further enhancing quality.

Kyu Tae Yoo, CEO of Samsung Medison, said, "Samsung Medison will continue to develop next-generation medical technologies to provide better diagnostic experiences for both medical professionals and patients." Yoo added, "We will combine the trust built with global medical professionals over the past 40 years with proactive investment to be reborn as a leading global diagnostic device company."